

Stuart J Pocock

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8240246/stuart-j-pocock-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

387 papers	81,899 citations	97 h-index	285 g-index
414 ext. papers	104,337 ext. citations	11.4 avg, IF	7.75 L-index

#	Paper	IF	Citations
387	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy.. <i>JACC: Cardiovascular Interventions</i> , 2022 , 15, 282-282	5	0
386	Effect of continuing versus stopping pre-stroke antihypertensive agents within 12'h on outcome after stroke: A subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial.. <i>EClinicalMedicine</i> , 2022 , 44, 101274	11.3	1
385	Early Benefit with Empagliflozin in Heart Failure with Preserved Ejection Fraction Insights from the EMPEROR-Preserved Trial.. <i>European Journal of Heart Failure</i> , 2022 ,	12.3	4
384	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1129-1137	15.1	1
383	Covariate Adjustment in Cardiovascular Randomized Controlled Trials: Its Value, Current Practice, and Need for Improvement.. <i>JACC: Heart Failure</i> , 2022 , 10, 297-305	7.9	0
382	Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.. <i>Lancet, The</i> , 2022 , 399, 1401-1410	40	11
381	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 , 7, 453-459	6.4	1
380	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. <i>European Heart Journal</i> , 2021 ,	9.5	26
379	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2021 ,	18.1	3
378	Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2021 ,	16.7	12
377	A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry. <i>Lancet, The</i> , 2021 , 398, 1974-1983	40	7
376	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. <i>EuroIntervention</i> , 2021 , 17, e898-e909	3.1	11
375	Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. <i>BMC Medical Research Methodology</i> , 2021 , 21, 218	4.7	0
374	The Clinical outcomes, healthcare resource utilization, and related costs (COHERENT) model. Application in heart failure patients. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021 ,	0.7	1
373	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021 ,	9.5	17
372	Relationship between nitrate headache and outcome in patients with acute stroke: results from the efficacy of nitric oxide in stroke (ENOS) trial. <i>Stroke and Vascular Neurology</i> , 2021 , 6, 180-186	9.1	0
371	Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2021 , 14, e007347	7.6	4

370	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1397-1407	15.1	32
369	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 1381-1392	15.1	30
368	Blood pressure reduction and anti-hypertensive treatment choice: A post-hoc analysis of the SPRINT trial. <i>Clinical Cardiology</i> , 2021 , 44, 665-674	3.3	1
367	Prioritised endpoints for device-based hypertension trials: the win ratio methodology. <i>EuroIntervention</i> , 2021 , 16, e1496-e1502	3.1	5
366	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation: The ARC-High Bleeding Risk Trade-off Model. <i>JAMA Cardiology</i> , 2021 , 6, 410-419	16.2	13
365	Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial. <i>Circulation: Heart Failure</i> , 2021 , 14, e008075	7.6	2
364	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021 , 42, 4442-4451	9.5	6
363	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1529-1538	12.3	7
362	Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2909-2919	15.1	21
361	Lowering systolic blood pressure to 120 mmHg or The Lancet's true grit. <i>European Heart Journal</i> , 2021 , 42, 2052-2059	9.5	1
360	Implications of Biomarker Discordance After Coronary Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 2978-2980	15.1	
359	Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , 2021 , 10, e021965	6	9
358	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. <i>Circulation</i> , 2021 , 143, 326-336	16.7	74
357	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. <i>Circulation</i> , 2021 , 143, 310-321	16.7	55
356	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021 , 231, 121-127	4.9	16
355	Long-term antiplatelet therapy in medically managed non-ST-segment elevation acute coronary syndromes: The EPICOR Asia study. <i>International Journal of Cardiology</i> , 2021 , 327, 19-24	3.2	1
354	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status: Results From the EMPEROR-Reduced Trial. <i>Circulation</i> , 2021 , 143, 337-349	16.7	80
353	Global patterns of comprehensive cardiovascular risk factor control in patients with type 2 diabetes mellitus: Insights from the DISCOVER study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 39-48	6.7	4

352	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021 , 42, 671-680	9.5	36
351	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021 , 42, 1203-1212	9.5	34
350	Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary Syndromes. <i>Journal of Cardiovascular Translational Research</i> , 2021 , 14, 790-798	3.3	0
349	Health-related quality of life 1-3 years post-myocardial infarction: its impact on prognosis. <i>Open Heart</i> , 2021 , 8,	3	3
348	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 444-456	5	3
347	Long-Term Antithrombotic Therapy and Clinical Outcomes in Patients with Acute Coronary Syndrome and Renal Impairment: Insights from EPICOR and EPICOR Asia. <i>American Journal of Cardiovascular Drugs</i> , 2021 , 21, 471-482	4	
346	Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1434-1446	5	1
345	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration. Translation to Russian. <i>Digital Diagnostics</i> , 2021 , 2, 119-169	1.8	1
344	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. <i>Circulation</i> , 2021 , 144, 1284-1294	16.7	30
343	Empagliflozin and Major Renal Outcomes in Heart Failure. <i>New England Journal of Medicine</i> , 2021 , 385, 1531-1533	59.2	19
342	Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. <i>Circulation</i> , 2021 , 144, 1476-1484	16.7	24
341	Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. <i>European Heart Journal</i> , 2021 , 42, 4683-4693	9.5	5
340	Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021 ,	6.4	3
339	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021 , 42, 4455-4464	9.5	5
338	Primary and Secondary Outcome Reporting in Randomized Trials: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 827-839	15.1	1
337	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 1798-1799	12.3	4
336	Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1028-1038	15.1	5
335	A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions. <i>Contemporary Clinical Trials Communications</i> , 2021 , 23, 100818	1.8	1

334	Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 1032-1041	16.2	8
333	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1321-1332	15.1	10
332	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 1337-1348	15.1	8
331	Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. <i>European Heart Journal</i> , 2021 , 42, 4624-4634	9.5	6
330	Diabetes association with self-reported health, resource utilization, and prognosis post-myocardial infarction. <i>Clinical Cardiology</i> , 2020 , 43, 1352-1361	3.3	1
329	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2020 , 43, 1546-1552	14.6	38
328	Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e008603	6	13
327	Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis. <i>European Journal of Heart Failure</i> , 2020 , 22, 1803-1813	12.3	27
326	Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: Findings from the EPICOR Asia study. <i>International Journal of Cardiology</i> , 2020 , 315, 1-8	3.2	3
325	Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT. <i>European Journal of Heart Failure</i> , 2020 , 22, 1615-1624	12.3	9
324	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020 , 41, 2109-2117	9.5	42
323	Antithrombotic management and long-term outcomes following percutaneous coronary intervention for acute coronary syndrome in Asia. <i>International Journal of Cardiology</i> , 2020 , 310, 16-22	3.2	5
322	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. <i>Lancet, The</i> , 2020 , 395, 1444-1451	40	166
321	Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e008226	6	9
320	A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data. <i>Drug Safety</i> , 2020 , 43, 623-633	5.1	7
319	Long-term antithrombotic management patterns in Asian patients with acute coronary syndrome: 2-year observations from the EPICOR Asia study. <i>Clinical Cardiology</i> , 2020 , 43, 999-1008	3.3	4
318	Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design. <i>Clinical Research in Cardiology</i> , 2020 , 109, 289-302	6.1	15
317	Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 590-604	15.1	61

316	Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. <i>International Journal of Cardiology</i> , 2020 , 311, 7-14	3.2	4
315	Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease: The EXCEL Trial. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 375-387	5	26
314	Prolonged dual antiplatelet therapy in patients with non-ST-segment elevation myocardial infarction: 2-year findings from EPICOR Asia. <i>Clinical Cardiology</i> , 2020 , 43, 346-354	3.3	3
313	Prasugrel use and clinical outcomes by age among patients undergoing PCI for acute coronary syndrome: from the PROMETHEUS study. <i>Clinical Research in Cardiology</i> , 2020 , 109, 725-734	6.1	4
312	1-Year Clinical Outcomes of All 'Comers' Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 820-830	5	6
311	Yoga-Based Cardiac Rehabilitation After Acute Myocardial Infarction: A Randomized Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1551-1561	15.1	25
310	Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2403-2413	15.1	34
309	Ticagrelor With or Without Aspirin After Complex PCI. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 2414-2424	15.1	58
308	Long-Term Outcome of Acute Coronary Syndromes in Patients on Chronic Oral Anticoagulants: Data from the EPICOR Study. <i>Current Vascular Pharmacology</i> , 2020 , 18, 92-99	3.3	
307	Use of the Win Ratio in Cardiovascular Trials. <i>JACC: Heart Failure</i> , 2020 , 8, 441-450	7.9	13
306	Predicting risk of cardiovascular events 1 to 3 years post-myocardial infarction using a global registry. <i>Clinical Cardiology</i> , 2020 , 43, 24-32	3.3	6
305	Glycaemic control in patients with type 2 diabetes initiating second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 66-78	6.7	8
304	Cardiovascular risk associated with serum potassium in the context of mineralocorticoid receptor antagonist use in patients with heart failure and left ventricular dysfunction. <i>European Journal of Heart Failure</i> , 2020 , 22, 1402-1411	12.3	10
303	Estimating the Lifetime Benefits of Treatments for Heart Failure. <i>JACC: Heart Failure</i> , 2020 , 8, 984-995	7.9	2
302	Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. <i>European Heart Journal</i> , 2020 , 41, 3533-3545	9.5	37
301	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. <i>European Heart Journal</i> , 2020 , 41, 3743-3749	9.5	45
300	Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 2393-2398	12.3	9
299	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet, The</i> , 2020 , 396, 1895-1904	40	162

298	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. <i>European Journal of Heart Failure</i> , 2020 , 22, 2383-2392	12.3	41
297	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 949-959	18.1	14
296	Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme. <i>BMJ Open</i> , 2020 , 10, e034613	3	0
295	Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1609-1621	15.1	26
294	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. <i>New England Journal of Medicine</i> , 2020 , 383, 1413-1424	59.2	1099
293	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. <i>Lancet, The</i> , 2020 , 396, 819-829	40	355
292	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 1468-1483	15.1	16
291	The win ratio approach for composite endpoints: practical guidance based on previous experience. <i>European Heart Journal</i> , 2020 , 41, 4391-4399	9.5	16
290	Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention-Results from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 95, 885-892	2.7	3
289	Effect of hospital volume on 90-day mortality after radical cystectomy for bladder cancer in Spain. <i>World Journal of Urology</i> , 2020 , 38, 1221-1228	4	6
288	In-Hospital Coronary Revascularization Rates and Post-Discharge Mortality Risk in Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 1454-1461	15.1	20
287	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. <i>New England Journal of Medicine</i> , 2019 , 381, 1820-1830	59.2	265
286	Ticagrelor with or without Aspirin in High-Risk Patients after PCI. <i>New England Journal of Medicine</i> , 2019 , 381, 2032-2042	59.2	395
285	Raised blood pressure and risk of dementia. <i>European Heart Journal</i> , 2019 , 40, 785-786	9.5	5
284	Effect of Barthel Index on the Risk of Thirty-Day Mortality in Patients With Acute Heart Failure Attending the Emergency Department: A Cohort Study of Nine Thousand Ninety-Eight Patients From the Epidemiology of Acute Heart Failure in Emergency Departments Registry. <i>Annals of Emergency Medicine</i> , 2019 , 73, 589-598	2.1	14
283	Analysis of How Emergency Physicians' Decisions to Hospitalize or Discharge Patients With Acute Heart Failure Match the Clinical Risk Categories of the MEESSE-AHF Scale. <i>Annals of Emergency Medicine</i> , 2019 , 74, 204-215	2.1	14
282	Development of a Yoga-Based Cardiac Rehabilitation (Yoga-CaRe) Programme for Secondary Prevention of Myocardial Infarction. <i>Evidence-based Complementary and Alternative Medicine</i> , 2019 , 2019, 7470184	2.3	9
281	Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2791-2802	15.1	152

280	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019 , 40, 2632-2653	9.5	169
279	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019 , 140, 240-261	16.7	183
278	Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 983-992	5	6
277	Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007133	6	10
276	Statistical Appraisal of 6 Recent Clinical Trials in Cardiology: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2740-2755	15.1	14
275	Are risk minimization measures for approved drugs in Europe effective? A systematic review. <i>Expert Opinion on Drug Safety</i> , 2019 , 18, 443-454	4.1	13
274	Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study. <i>Diabetes Research and Clinical Practice</i> , 2019 , 151, 20-32	7.4	31
273	Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. <i>New England Journal of Medicine</i> , 2019 , 380, 1695-1705	59.2	1849
272	Associations between use of prasugrel vs clopidogrel and outcomes by type of acute coronary syndrome: an analysis from the PROMETHEUS registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 42-51	5.1	3
271	Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1616-1628	15.1	37
270	The Usefulness of the MEESSE Score for Risk Stratification of Patients With Acute Heart Failure at the Emergency Department. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019 , 72, 198-207	0.7	3
269	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. <i>Thrombosis and Haemostasis</i> , 2019 , 119, 1704-1711	7	2
268	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 1270-1278	12.3	73
267	Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: Results from the global DISCOVER study programme. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2474-2485	6.7	19
266	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. <i>European Heart Journal</i> , 2019 ,	9.5	44
265	Nonproportional Hazards for Time-to-Event Outcomes in Clinical Trials: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 2102-2112	15.1	30
264	Tranexamic acid to improve functional status in adults with spontaneous intracerebral haemorrhage: the TICH-2 RCT. <i>Health Technology Assessment</i> , 2019 , 23, 1-48	4.4	10
263	Renal function stratified dose comparisons of eplerenone versus placebo in the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2019 , 21, 345-351	12.3	28

262	External Validation of the MEESSI Acute Heart Failure Risk Score: A Cohort Study. <i>Annals of Internal Medicine</i> , 2019 , 170, 248-256	8	19
261	MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT. <i>JACC: Heart Failure</i> , 2019 , 7, 1012-1021	7.9	14
260	Associations between change in blood pressure and functional outcome, early events and death: results from the Efficacy of Nitric Oxide in Stroke trial. <i>Journal of Hypertension</i> , 2019 , 37, 2104-2109	1.9	2
259	Impact of eplerenone on major cardiovascular outcomes in patients with systolic heart failure according to baseline heart rate. <i>Clinical Research in Cardiology</i> , 2019 , 108, 806-814	6.1	5
258	Predictors of all-cause mortality and ischemic events within and beyond 1 year after an acute coronary syndrome: Results from the EPICOR registry. <i>Clinical Cardiology</i> , 2019 , 42, 111-119	3.3	26
257	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019 , 12, e004945	5.8	3
256	Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial. <i>European Heart Journal</i> , 2019 , 40, 743-751	9.5	44
255	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2019 , 123, 709-716	3	3
254	Effectiveness and cost-effectiveness of a Yoga-based Cardiac Rehabilitation (Yoga-CaRe) program following acute myocardial infarction: Study rationale and design of a multi-center randomized controlled trial. <i>International Journal of Cardiology</i> , 2019 , 280, 14-18	3.2	14
253	Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 94, 53-60	2.7	1
252	Response by Claggett et al to Letter Regarding Article, "Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials". <i>Circulation</i> , 2019 , 139, 422-423	16.7	
251	The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 93, E112-E119	2.7	6
250	Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2019 , 275, 31-35	3.2	10
249	Health-related quality of life in people with type 2 diabetes participating in the LEADER trial. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 525-532	6.7	11
248	Predicting two-year mortality from discharge after acute coronary syndrome: An internationally-based risk score. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 727-737	4.3	21
247	Ambulance-delivered transdermal glyceryl trinitrate versus sham for ultra-acute stroke: Rationale, design and protocol for the Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2) trial (ISRCTN26986053). <i>International Journal of Stroke</i> , 2019 , 14, 191-206	6.3	13
246	Impact of known or new-onset atrial fibrillation on 2-year cardiovascular event rate in patients with acute coronary syndromes: results from the prospective EPICOR Registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019 , 8, 121-129	4.3	19
245	Patients with acute heart failure discharged from the emergency department and classified as low risk by the MEESSI score (multiple risk estimate based on the Spanish emergency department scale): prevalence of adverse events and predictability. <i>Emergencias</i> , 2019 , 31, 5-14	0.9	13

244	Regional variations in hospital management and post-discharge mortality in patients with non-ST-segment elevation acute coronary syndrome. <i>Clinical Research in Cardiology</i> , 2018 , 107, 836-844	6.1	17
243	Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. <i>Canadian Journal of Cardiology</i> , 2018 , 34, 319-329	3.8	13
242	Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. <i>Lancet, The</i> , 2018 , 391, 850-859	4.0	72
241	Comparison of Time-to-First Event and Recurrent-Event Methods in Randomized Clinical Trials. <i>Circulation</i> , 2018 , 138, 570-577	16.7	38
240	Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e006144	6	15
239	Ever-Pregnant Female Blood Donors and Mortality Risk in Male Recipients. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 1048	27.4	3
238	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018 , 20, 125-133	12.3	186
237	Individualizing treatment choices in the systolic blood pressure intervention trial. <i>Journal of Hypertension</i> , 2018 , 36, 428-435	1.9	3
236	Therapeutic inertia in the treatment of hyperglycaemia in patients with type 2 diabetes: A systematic review. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 427-437	6.7	134
235	Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 754-765	15.1	39
234	Predictors of high-cost hospitalization in the treatment of acute coronary syndrome in Asia: findings from EPICOR Asia. <i>BMC Cardiovascular Disorders</i> , 2018 , 18, 139	2.3	8
233	Changes in HbA1c and weight, and treatment persistence, over the 18 months following initiation of second-line therapy in patients with type 2 diabetes: results from the United Kingdom Clinical Practice Research Datalink. <i>BMC Medicine</i> , 2018 , 16, 116	11.4	28
232	Critical Appraisal of the 2018 ACC Scientific Sessions Late-Breaking Trials From a Statistician's Perspective. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 2957-2969	15.1	16
231	Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. <i>Lancet, The</i> , 2018 , 392, 1127-1137	4.0	43
230	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , 2018 , 122, 1638-1646	3	12
229	Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department. <i>Annals of Internal Medicine</i> , 2018 , 168, 899-900	8	1
228	Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. <i>Health Technology Assessment</i> , 2018 , 22, 1-76	4.4	6
227	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 504-510	12.3	37

226	Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second-line therapy after metformin monotherapy: Retrospective data for 10 256 individuals from the United Kingdom and Germany. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 389-399	6.7	31
225	Statistical analysis plan for the 'Rapid Intervention with Glyceryl trinitrate in Hypertensive stroke Trial-2 (RIGHT-2)'. <i>European Stroke Journal</i> , 2018 , 3, 193-196	5.6	4
224	Central adjudication of serious adverse events did not affect trial's safety results: Data from the Efficacy of Nitric Oxide in Stroke (ENOS) trial. <i>PLoS ONE</i> , 2018 , 13, e0208142	3.7	6
223	Central masked adjudication of stroke diagnosis at trial entry offered no advantage over diagnosis by local clinicians: Secondary analysis and simulation. <i>Contemporary Clinical Trials Communications</i> , 2018 , 12, 176-181	1.8	5
222	Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). <i>Cardiovascular Diabetology</i> , 2018 , 17, 150	8.7	73
221	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. <i>Lancet, The</i> , 2018 , 391, 2346-2355	4.0	358
220	Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. <i>Lancet, The</i> , 2018 , 391, 2107-2115	4.0	195
219	Percutaneous coronary intervention for stable angina in ORBITA. <i>Lancet, The</i> , 2018 , 392, 26-27	4.0	
218	Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, 629-637	2.7	45
217	Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 345-357	15.1	267
216	Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term risk, clinical management and healthcare Resource utilization of stable coronary artery disease (TIGRIS) observational study. <i>International Journal of Cardiology</i> , 2017 , 236, 54-60	3.2	19
215	International patterns of dual antiplatelet therapy duration after acute coronary syndromes. <i>Heart</i> , 2017 , 103, 132-138	5.1	36
214	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. <i>American Heart Journal</i> , 2017 , 188, 73-81	4.9	20
213	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , 2017 , 218, 133-138	3.2	8
212	Towards an improved global understanding of treatment and outcomes in people with type 2 diabetes: Rationale and methods of the DISCOVER observational study program. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1188-1196	3.2	37
211	Improving public health by improving clinical trial guidelines and their application. <i>European Heart Journal</i> , 2017 , 38, 1632-1637	9.5	15
210	Association Between Clinical Pathways Leading to Medical Management and Prognosis in Patients With NSTEMI. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017 , 70, 817-824	0.7	1
209	Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 645-654	5	15

208	Personalising the decision for prolonged dual antiplatelet therapy: development, validation and potential impact of prognostic models for cardiovascular events and bleeding in myocardial infarction survivors. <i>European Heart Journal</i> , 2017 , 38, 1048-1055	9.5	33
207	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017 , 19, 718-727	12.3	15
206	Effect of eplerenone in patients with heart failure and reduced ejection fraction: potential effect modification by abdominal obesity. Insight from the EMPHASIS-HF trial. <i>European Journal of Heart Failure</i> , 2017 , 19, 1186-1197	12.3	55
205	Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1846-1857	15.1	34
204	Predicting 30-Day Mortality for Patients With Acute Heart Failure in the Emergency Department: A Cohort Study. <i>Annals of Internal Medicine</i> , 2017 , 167, 698-705	8	94
203	Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot 'Prevention of Decline in Cognition after Stroke Trial' (PODCAST) Randomised Controlled Trial. <i>PLoS ONE</i> , 2017 , 12, e0164608	3.7	41
202	Statistical analysis plan for the 'Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage' (TICH-2) trial. <i>Trials</i> , 2017 , 18, 607	2.8	12
201	Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study. <i>European Heart Journal</i> , 2017 , 38, 961-969	9.5	45
200	The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017 , 19, 1390-1400	12.3	111
199	White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10, e005416	6	15
198	Characteristics and outcomes of medically managed patients with non-ST-segment elevation acute coronary syndromes: Insights from the multinational EPICOR Asia study. <i>International Journal of Cardiology</i> , 2017 , 243, 15-20	3.2	10
197	Relaci3n entre las situaciones cl3nicas que llevan al tratamiento exclusivamente farmacol3gico del SCASEST y su pron3stico. <i>Revista Espanola De Cardiologia</i> , 2017 , 70, 817-824	1.5	8
196	Infections Up to 76 Days After Stroke Increase Disability and Death. <i>Translational Stroke Research</i> , 2017 , 8, 541-548	7.8	15
195	Global geographical variations in ST-segment elevation myocardial infarction management and post-discharge mortality. <i>International Journal of Cardiology</i> , 2017 , 245, 27-34	3.2	54
194	Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 2017-2025	5	27
193	Challenges in the Design and Interpretation of Noninferiority Trials: Insights From Recent Stent Trials. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 894-903	15.1	15
192	Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2979-2991	15.1	153
191	Predicting Subclinical Atherosclerosis in Low-Risk Individuals: Ideal Cardiovascular Health Score and Fuster-BEWAT Score. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2463-2473	15.1	31

190	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). <i>American Journal of Cardiology</i> , 2017 , 120, 904-910	3	7
189	2-Year Outcomes of High 'Bleeding Risk' Patients After Polymer-Free Drug-Coated Stents. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 162-171	15.1	91
188	Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial. <i>International Journal of Stroke</i> , 2017 , 12, 524-538	6.3	4
187	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, E217-E225	2.7	10
186	Rationale and design of the long-Term risk, clinical management, and healthcare Resource utilization of stable coronary artery disease in post-myocardial infarction patients (TIGRIS) study. <i>Clinical Cardiology</i> , 2017 , 40, 1197-1204	3.3	7
185	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. <i>Lancet, The</i> , 2017 , 390, 2160-2170	40	406
184	Incidence and impact of acute kidney injury in patients with acute coronary syndromes treated with coronary artery bypass grafting: Insights from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) and Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trials. <i>American Heart Journal</i> , 2016 , 171, 40-7	4.9	24
183	The Primary Outcome Fails - What Next?. <i>New England Journal of Medicine</i> , 2016 , 375, 861-70	59.2	152
182	Association Between a Social-Business Eating Pattern and Early Asymptomatic Atherosclerosis. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 805-14	15.1	18
181	Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1461-9	5	27
180	Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. <i>American Journal of Cardiology</i> , 2016 , 118, 1661-1668	3	5
179	Regression to the Mean in SYMPPLICITY HTN-3: Implications for Design and Reporting of Future Trials. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2016-2025	15.1	36
178	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2016 , 375, 2223-2235	59.2	603
177	RAPID INTERVENTION WITH GLYCERYL TRINITRATE IN HYPERTENSIVE STROKE TRIAL-2 (RIGHT-2): SAFETY AND EFFICACY OF TRANSDERMAL GLYCERYL TRINITRATE, A NITRIC OXIDE DONOR. <i>Emergency Medicine Journal</i> , 2016 , 33, e13.2-e14	1.5	2
176	Short Telomere Load, Telomere Length, and Subclinical Atherosclerosis: The PESA Study. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2467-76	15.1	44
175	Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016 , 375, 311-22	59.2	3606
174	Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study. <i>European Journal of Heart Failure</i> , 2016 , 18, 1175-81	12.3	11
173	Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2016 , 87, 391-400	2.7	7

172	Opportunities for improvement in anti-thrombotic therapy and other strategies for the management of acute coronary syndromes: Insights from EPICOR, an international study of current practice patterns. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2016 , 5, 3-12	4.3	36
171	Oseltamivir for influenza - Authors' reply. <i>Lancet, The</i> , 2016 , 387, 125	4.0	
170	The rise, fall, and possible resurrection of renal denervation. <i>Nature Reviews Cardiology</i> , 2016 , 13, 238-44	4.8	28
169	The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. <i>American Heart Journal</i> , 2016 , 171, 82-91	4.9	104
168	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1349-57	5	36
167	A win ratio approach to comparing continuous non-normal outcomes in clinical trials. <i>Pharmaceutical Statistics</i> , 2016 , 15, 238-45	1	27
166	Statistical Essentials in the Design and Analysis of Clinical Trials 2016 , 296-300		
165	The Nature of the P Value. <i>New England Journal of Medicine</i> , 2016 , 375, 2205-2206	59.2	2
164	Bleeding Events Before Coronary Angiography in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2608-2618	15.1	3
163	Prehospital and in-hospital use of healthcare resources in patients surviving acute coronary syndromes: an analysis of the EPICOR registry. <i>Open Heart</i> , 2016 , 3, e000347	3	4
162	Analysis of recurrent events with an associated informative dropout time: Application of the joint frailty model. <i>Statistics in Medicine</i> , 2016 , 35, 2195-205	2.3	31
161	Cryoballoon or Radiofrequency Ablation for Paroxysmal Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2016 , 374, 2235-45	59.2	905
160	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 2224-2234	15.1	306
159	Intravenous tranexamic acid for hyperacute primary intracerebral hemorrhage: Protocol for a randomized, placebo-controlled trial. <i>International Journal of Stroke</i> , 2016 , 11, 683-94	6.3	42
158	Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2016 , 2, 200-5	6.4	21
157	The Primary Outcome Is Positive - Is That Good Enough?. <i>New England Journal of Medicine</i> , 2016 , 375, 971-9	59.2	78
156	Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. <i>American Heart Journal</i> , 2016 , 182, 125-134	4.9	84
155	10-Year Mortality Outcome of a Routine Invasive Strategy Versus a Selective Invasive Strategy in Non-ST-Segment Elevation Acute Coronary Syndrome: The British Heart Foundation RITA-3 Randomized Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 511-20	15.1	40

154	Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2015 , 36, 2310-7	9.5	20
153	The perils of surrogate endpoints. <i>European Heart Journal</i> , 2015 , 36, 2212-8	9.5	41
152	Prevalence, Vascular Distribution, and Multiterritorial Extent of Subclinical Atherosclerosis in a Middle-Aged Cohort: The PESA (Progression of Early Subclinical Atherosclerosis) Study. <i>Circulation</i> , 2015 , 131, 2104-13	16.7	239
151	Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the BioImage study. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1065-74	15.1	256
150	BMI and risk of dementia in two million people over two decades: a retrospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 431-436	18.1	247
149	Effect of ivabradine on numbers needed to treat for the prevention of recurrent hospitalizations in heart failure patients. <i>Current Medical Research and Opinion</i> , 2015 , 31, 1903-9	2.5	9
148	Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1273-1285	15.1	79
147	Making Sense of Statistics in Clinical Trial Reports: Part 1 of a 4-Part Series on Statistics for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2536-49	15.1	35
146	Association between anthropometry and high blood pressure in a representative sample of preschoolers in madrid. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015 , 68, 477-84	0.7	2
145	Contemporary inter-hospital transfer patterns for the management of acute coronary syndrome patients: findings from the EPICOR study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 254-62	4.3	13
144	Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388). <i>International Journal of Stroke</i> , 2015 , 10, 1159-65	6.3	19
143	Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). <i>European Journal of Heart Failure</i> , 2015 , 17, 707-16	12.3	15
142	Rationale, Design, and Baseline Characteristics of the EPICOR Asia Study (Long-term follow-up of antithrombotic management patterns in Acute CORonary Syndrome patients in Asia). <i>Clinical Cardiology</i> , 2015 , 38, 511-9	3.3	21
141	Oseltamivir for influenza - Authors' reply. <i>Lancet, The</i> , 2015 , 386, 1135-6	4.0	5
140	Baseline characteristics, analysis plan and report on feasibility for the Prevention Of Decline in Cognition After Stroke Trial (PODCAST). <i>Trials</i> , 2015 , 16, 509	2.8	5
139	Differing prognostic value of pulse pressure in patients with heart failure with reduced or preserved ejection fraction: results from the MAGGIC individual patient meta-analysis. <i>European Heart Journal</i> , 2015 , 36, 1106-14	9.5	37
138	Design of Major Randomized Trials: Part 3 of a 4-Part Series on Statistics for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2757-2766	15.1	38
137	Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2648-2662	15.1	57

136	Predictors of one-year mortality at hospital discharge after acute coronary syndromes: A new risk score from the EPICOR (long-term follow up of antithrombotic management patterns in acute CORonary syndrome patients) study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015 , 4, 509-17	4.3	52
135	Diagnostic and Prognostic Implications of Coronary Flow Capacity: A Comprehensive Cross-Modality Physiological Concept in Ischemic Heart Disease. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1670-80	5	59
134	Challenging Issues in Clinical Trial Design: Part 4 of a 4-Part Series on Statistics for Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 2886-2898	15.1	33
133	Does midlife obesity really lower dementia risk? - Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2015 , 3, 501-2	18.1	2
132	Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 27-38	15.1	54
131	Incidence and impact of totally occluded culprit coronary arteries in patients presenting with non-ST-segment elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2015 , 115, 428-33	3	18
130	Effects of long-term use of cardiovascular drugs. <i>Lancet, The</i> , 2015 , 385, 325	40	6
129	Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 1298-1310	15.1	252
128	Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. <i>Lancet, The</i> , 2015 , 385, 1729-1737	40	351
127	Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial. <i>International Journal of Stroke</i> , 2015 , 10, 449-51	6.3	19
126	VALIDATION OF A QUESTIONNAIRE TO MEASURE OVERALL MEDITERRANEAN LIFESTYLE HABITS FOR RESEARCH APPLICATION: THE MEDITERRANEAN LIFESTYLE INDEX (MEDLIFE). <i>Nutricion Hospitalaria</i> , 2015 , 32, 1153-63	1	17
125	Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 15-20	15.1	56
124	A polypill strategy to improve adherence: results from the FOCUS project. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 2071-82	15.1	202
123	The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2014 , 15, 300	2.8	63
122	Do current clinical trials meet society's needs?: a critical review of recent evidence. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1615-28	15.1	44
121	Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). <i>JACC: Heart Failure</i> , 2014 , 2, 289-97	7.9	84
120	Current challenges for clinical trials of cardiovascular medical devices. <i>International Journal of Cardiology</i> , 2014 , 175, 30-7	3.2	31
119	Large streamlined trials in cardiovascular disease. <i>European Heart Journal</i> , 2014 , 35, 544-8	9.5	19

118	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. <i>International Journal of Surgery</i> , 2014 , 12, 1495-9	7.5	3267
117	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. <i>International Journal of Surgery</i> , 2014 , 12, 1500-24	7.5	1057
116	Feasibility and exploratory efficacy evaluation of the Embrella Embolic Deflector system for the prevention of cerebral emboli in patients undergoing transcatheter aortic valve replacement: the PROTAVI-C pilot study. <i>JACC: Cardiovascular Interventions</i> , 2014 , 7, 1146-55	5	98
115	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. <i>European Journal of Heart Failure</i> , 2014 , 16, 33-40	12.3	141
114	2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). <i>European Heart Journal</i> , 2014 , 35, 2383-431	9.5	849
113	Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. <i>Circulation: Heart Failure</i> , 2014 , 7, 895-902	7.6	25
112	Long-term benefit of early pre-reperfusion metoprolol administration in patients with acute myocardial infarction: results from the METOCARD-CNIC trial (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2356-62	15.1	125
111	Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. <i>Journal of Biomedical Research</i> , 2014 , 28, 349-59	1.5	16
110	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet, The</i> , 2013 , 382, 1714-22	40.2	405
109	Effect of early metoprolol on infarct size in ST-segment-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: the Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction (METOCARD-CNIC) trial. <i>Circulation</i> , 2013 , 128, 1495-503	16.7	249
108	Learning from recent trials and shaping the future of acute heart failure trials. <i>American Heart Journal</i> , 2013 , 166, 629-35	4.9	21
107	Bivalirudin started during emergency transport for primary PCI. <i>New England Journal of Medicine</i> , 2013 , 369, 2207-17	59.2	372
106	Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy. <i>European Heart Journal</i> , 2013 , 34, 1621-9	9.5	8
105	Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids. <i>Trials</i> , 2013 , 14, 401	2.8	13
104	A win ratio approach to comparing ordinal or non-normal outcomes in clinical trials. <i>Trials</i> , 2013 , 14,	2.8	1
103	International differences in treatment effect: do they really exist and why?. <i>European Heart Journal</i> , 2013 , 34, 1846-52	9.5	37
102	Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. <i>European Heart Journal</i> , 2013 , 34, 1404-13	9.5	595
101	The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. <i>European Heart Journal</i> , 2013 , 34, 2823-9	9.5	61

100	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013 , 15, 1082-94	12.3	143
99	Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 2594-604	27.4	710
98	Impact of major bleeding and blood transfusions after cardiac surgery: analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. <i>American Heart Journal</i> , 2012 , 163, 522-9	4.9	52
97	The Use of Figures in Epidemiological Publications: A Survey of Current Practice and Consequent Recommendations 2012 , 71-83		
96	The science of risk models. <i>European Journal of Preventive Cardiology</i> , 2012 , 19, 7-13	3.9	10
95	When to stop a clinical trial early for benefit: lessons learned and future approaches. <i>Circulation: Heart Failure</i> , 2012 , 5, 294-302	7.6	18
94	The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. <i>European Heart Journal</i> , 2012 , 33, 176-82	9.5	231
93	Eplerenone in patients with systolic heart failure and mild symptoms. <i>New England Journal of Medicine</i> , 2011 , 364, 11-21	59.2	1890
92	Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. <i>Lancet, The</i> , 2011 , 377, 2193-204	40	358
91	Adaptive increase in sample size when interim results are promising: a practical guide with examples. <i>Statistics in Medicine</i> , 2011 , 30, 3267-84	2.3	184
90	Authors' response to Comment on adaptive increase in sample size when interim results are promising <i>Statistics in Medicine</i> , 2011 , 30, 3302-3303	2.3	3
89	Transcatheter versus surgical aortic-valve replacement in high-risk patients. <i>New England Journal of Medicine</i> , 2011 , 364, 2187-98	59.2	4230
88	Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiogram to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial	5	274
87	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. <i>European Journal of Heart Failure</i> , 2010 , 12, 557-65	12.3	51
86	Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. <i>Circulation</i> , 2010 , 121, 43-51	16.7	100
85	Randomized trials, statistics, and clinical inference. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 428-31	15.1	29
84	Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2435-45	15.1	403
83	Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. <i>New England Journal of Medicine</i> , 2010 , 363, 1597-607	59.2	4801

82	A risk score to predict bleeding in patients with acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2010 , 55, 2556-66	15.1	479
81	Categorisation of continuous risk factors in epidemiological publications: a survey of current practice. <i>Epidemiologic Perspectives and Innovations</i> , 2010 , 7, 9		68
80	Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUTY trial. <i>European Heart Journal</i> , 2009 , 30, 1457-66	9.5	260
79	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , 2009 , 11, 170-7	12.3	247
78	Ferric carboxymaltose in patients with heart failure and iron deficiency. <i>New England Journal of Medicine</i> , 2009 , 361, 2436-48	59.2	1178
77	Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. <i>New England Journal of Medicine</i> , 2009 , 360, 1946-59	59.2	577
76	Translating statistical findings into plain English. <i>Lancet, The</i> , 2009 , 373, 1926-8	40	54
75	Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. <i>Lancet, The</i> , 2009 , 373, 1190-7	40	531
74	Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. <i>Lancet, The</i> , 2009 , 373, 2125-35	40	1059
73	Insulin glargine and malignancy: an unwarranted alarm. <i>Lancet, The</i> , 2009 , 374, 511-3	40	112
72	Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. <i>European Heart Journal</i> , 2009 , 30, 338-45	9.5	19
71	Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 23-32	15.1	132
70	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Journal of Clinical Epidemiology</i> , 2008 , 61, 344-9	5.7	4750
69	How to interpret figures in reports of clinical trials. <i>BMJ, The</i> , 2008 , 336, 1166-9	5.9	17
68	Use of ordinal outcomes in vascular prevention trials: comparison with binary outcomes in published trials. <i>Stroke</i> , 2008 , 39, 2817-23	6.7	34
67	Bivalirudin during primary PCI in acute myocardial infarction. <i>New England Journal of Medicine</i> , 2008 , 358, 2218-30	59.2	1457
66	Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008 , 29, 2641-50	9.5	135
65	More on subgroup analyses in clinical trials. <i>New England Journal of Medicine</i> , 2008 , 358, 2076; author reply 2076-7	59.2	23

64	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>PLoS Medicine</i> , 2007 , 4, e296	11.6	2066
63	Figures in clinical trial reports: current practice & scope for improvement. <i>Trials</i> , 2007 , 8, 36	2.8	26
62	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Bulletin of the World Health Organization</i> , 2007 , 85, 867-72	8.2	613
61	Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , 2007 , 116, 627-36	16.7	264
60	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. <i>PLoS Medicine</i> , 2007 , 4, e297	11.6	1900
59	Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUTY Timing trial. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 591-602	27.4	226
58	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>BMJ, The</i> , 2007 , 335, 806-8	5.9	2821
57	Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUTY trial. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 298, 2497-506	27.4	185
56	Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , 2007 , 115, 3111-20	16.7	188
55	Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. <i>Circulation</i> , 2007 , 116, 1482-7	16.7	400
54	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Annals of Internal Medicine</i> , 2007 , 147, 573-7	8	2941
53	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. <i>Annals of Internal Medicine</i> , 2007 , 147, W163-94	8	765
52	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Epidemiology</i> , 2007 , 18, 800-4	3.1	763
51	Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. <i>Epidemiology</i> , 2007 , 18, 805-35	3.1	1174
50	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Preventive Medicine</i> , 2007 , 45, 247-51	4.3	630
49	The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. <i>Lancet, The</i> , 2007 , 370, 1453-7	4.0	5729
48	Safety of drug-eluting stents: demystifying network meta-analysis. <i>Lancet, The</i> , 2007 , 370, 2099-100	4.0	13
47	Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. <i>European Heart Journal</i> , 2007 , 28, 1936-43	8.5	192

46	Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 40-7	15.1	630
45	The simplest statistical test: how to check for a difference between treatments. <i>BMJ, The</i> , 2006 , 332, 1256-8	5.9	41
44	Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1152-60	27.4	908
43	Bivalirudin for patients with acute coronary syndromes. <i>New England Journal of Medicine</i> , 2006 , 355, 2203-16	59.2	1167
42	Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. <i>Circulation</i> , 2006 , 113, 986-94	16.7	194
41	Predictors of mortality and morbidity in patients with chronic heart failure. <i>European Heart Journal</i> , 2006 , 27, 65-75	9.5	680
40	Current controversies in data monitoring for clinical trials. <i>Clinical Trials</i> , 2006 , 3, 513-21	2.2	61
39	Risk score for predicting death, myocardial infarction, and stroke in patients with stable angina, based on a large randomised trial cohort of patients. <i>BMJ, The</i> , 2005 , 331, 869	5.9	87
38	The data monitoring experience in the Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2005 , 149, 939-43	4.9	23
37	When (not) to stop a clinical trial for benefit. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 2228-30	27.4	109
36	Eliciting and using expert opinions about influence of patient characteristics on treatment effects: a Bayesian analysis of the CHARM trials. <i>Statistics in Medicine</i> , 2005 , 24, 3805-21	2.3	23
35	Re: "quality of reporting of observational longitudinal research". <i>American Journal of Epidemiology</i> , 2005 , 162, 1032-3; author reply 1033	3.8	0
34	Data monitoring in randomized controlled trials: surveys of recent practice and policies. <i>Clinical Trials</i> , 2005 , 2, 22-33	2.2	20
33	Issues in regulatory guidelines for data monitoring committees. <i>Clinical Trials</i> , 2004 , 1, 162-9	2.2	17
32	Issues in the reporting of epidemiological studies: a survey of recent practice. <i>BMJ, The</i> , 2004 , 329, 883	5.9	183
31	The data monitoring experience in the MOXCON trial. <i>European Heart Journal</i> , 2004 , 25, 1974-8	9.5	29
30	Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions. <i>American Journal of Cardiology</i> , 2004 , 94, 1023-7	3	54
29	A major trial needs three statisticians: why, how and who?. <i>Statistics in Medicine</i> , 2004 , 23, 1535-9	2.3	16

28	The pros and cons of noninferiority trials. <i>Fundamental and Clinical Pharmacology</i> , 2003 , 17, 483-90	3.1	90
27	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet, The</i> , 2003 , 362, 759-66	4.0	1506
26	Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. <i>Statistics in Medicine</i> , 2002 , 21, 2917-30	2.3	749
25	Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. <i>Lancet, The</i> , 2002 , 359, 1686-9	4.0	328
24	Accounting For Non-Independent Observations In 2x2 Tables, With Application To Correcting For Family Clustering In Exposure-Risk Relationship Studies. <i>Journal of Modern Applied Statistical Methods</i> , 2002 , 1, 379-386	0.3	1
23	A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. <i>BMJ: British Medical Journal</i> , 2001 , 323, 75-81		170
22	Randomized clinical trials with added rescue medication: some approaches to their analysis and interpretation. <i>Statistics in Medicine</i> , 2001 , 20, 2995-3008	2.3	23
21	Randomized trials or observational tribulations?. <i>New England Journal of Medicine</i> , 2000 , 342, 1907-9	59.2	452
20	Subgroup analysis and other (mis)uses of baseline data in clinical trials. <i>Lancet, The</i> , 2000 , 355, 1064-9	4.0	878
19	Evaluation of antiarrhythmic drug efficacy in patients with an ICD: unlimited potential or replete with complexity and problems?. <i>Journal of Cardiovascular Electrophysiology</i> , 1999 , 10, 1534-49	2.7	5
18	Trials stopped early: too good to be true?. <i>Lancet, The</i> , 1999 , 353, 943-4	4.0	83
17	The agonising negative trend in monitoring of clinical trials. <i>Lancet, The</i> , 1999 , 354, 1983-8	4.0	111
16	The hope and the hazards of using compliance data in randomized controlled trials. <i>Statistics in Medicine</i> , 1998 , 17, 303-17	2.3	46
15	The hope and the hazards of using compliance data in randomized controlled trials 1998 , 17, 303		1
14	Linearly divergent treatment effects in clinical trials with repeated measures: efficient analysis using summary statistics. <i>Statistics in Medicine</i> , 1997 , 16, 2855-72	2.3	43
13	Statistical reporting of clinical trials with individual changes from allocated treatment. <i>Statistics in Medicine</i> , 1996 , 15, 249-62	2.3	21
12	The role of external evidence in data monitoring of a clinical trial. <i>Statistics in Medicine</i> , 1996 , 15, 1285-93; discussion 1295-7	2.3	11
11	STATISTICAL REPORTING OF CLINICAL TRIALS WITH INDIVIDUAL CHANGES FROM ALLOCATED TREATMENT 1996 , 15, 249		1

10	Life as an academic medical statistician and how to survive it. <i>Statistics in Medicine</i> , 1995 , 14, 209-22	2.3	11
9	Optimal Sequential Screening Guidelines for Quantitative Risk Factors Measured with Error. <i>Journal of the American Statistical Association</i> , 1995 , 90, 19-26	2.8	3
8	Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. <i>Statistics in Medicine</i> , 1994 , 13, 197-8	2.3	19
7	Statistical and ethical issues in monitoring clinical trials. <i>Statistics in Medicine</i> , 1993 , 12, 1459-69; discussion 1471-5	2.3	56
6	Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. <i>Statistics in Medicine</i> , 1992 , 11, 1685-704	2.3	500
5	Prediction of short-term survival with an application in primary biliary cirrhosis. <i>Statistics in Medicine</i> , 1992 , 11, 1731-45	2.3	29
4	Estimation issues in clinical trials and overviews. <i>Statistics in Medicine</i> , 1990 , 9, 657-71	2.3	70
3	Statistical problems in the reporting of clinical trials. A survey of three medical journals. <i>New England Journal of Medicine</i> , 1987 , 317, 426-32	59.2	549
2	Interim Analyses in Randomized Clinical Trials: Ramifications and Guidelines for Practitioners. <i>Biometrics</i> , 1987 , 43, 213	1.8	134
1	Statistical Essentials in the Design and Analysis of Clinical Trials491-501		